Crinetics Pharmaceuticals: Driehaus reports 0% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Crinetics Pharmaceuticals, Inc. (CRNX) is the issuer whose common stock is covered by Driehaus Capital Management LLC’s Schedule 13G/A amendment. Driehaus reported zero beneficially owned shares and stated it had ceased being a beneficial owner.
Key Figures
Beneficially owned shares: 0 shares
Ownership of class: 0%
Voting power: 0 sole; 0 shared
+1 more
4 metrics
Beneficially owned shares
0 shares
Driehaus Capital Management LLC reported this amount for Crinetics common stock.
Ownership of class
0%
Driehaus Capital Management LLC reported this percentage.
Voting power
0 sole; 0 shared
Driehaus Capital Management LLC reported no sole or shared voting power.
Dispositive power
0 sole; 0 shared
Driehaus Capital Management LLC reported no sole or shared dispositive power.
Key Terms
beneficial owner
1 terms
beneficial owner regulatory
"ceased being a beneficial owner"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.